Overview

Safety and Efficacy of Nebulized Nitroglycerin in Pulmonary Arterial Hypertension

Status:
COMPLETED
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
The 6th World Symposium on Pulmonary Hypertension, pre-capillary pulmonary hypertension (PH) has been defined as mean pulmonary arterial pressure (mPAP) \>20 mm Hg with a pulmonary arterial wedge pressure (PAWP) 15 mm Hg and pulmonary vascular resistance (PVR) 3 Wood units (WU). The current classification of PH categorizes clinical conditions associated with PH based on similar pathophysiology, etiologies, clinical presentation, hemodynamic characteristics and therapeutic management. PH is classified into five groups. The group 1 pulmonary arterial hypertension (PAH), which comprises of diverse diseases that result in similar pathological changes within the pulmonary vasculature. This includes idiopathic, familial, drug and toxin induced PAH and associated forms of PAH like systemic sclerosis, portal hypertension, congenital heart disease and human immunodeficiency virus (HIV). The remaining 4 groups of PH are secondary to other conditions and are usually referred to as secondary PH
Phase:
NA
Details
Lead Sponsor:
Mansoura University
Treatments:
Nitroglycerin